Clinical trial
A Study of rhuFab V2 (Ranibizumab) in Subjects With Subfoveal Choroidal…
NCT00090623 · Genentech, Inc., Industry · Completed
Key facts
| NCT number | NCT00090623 |
|---|---|
| Title | A Study of rhuFab V2 (Ranibizumab) in Subjects With Subfoveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration (AMD) |
| Official title | A Phase IIIb, Multicenter, Randomized, Double Masked, Sham Injection-Controlled Study of the Efficacy and Safety of Ranibizumab in Subjects With Subfoveal Choroidal Neovascularization (CNV) With or Without Classic CNV Secondary to Age Related Macular Degeneration |
| Lead sponsor | Genentech, Inc., Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Macular Degeneration |
| Intervention type | Drug |
| Interventions | rhuFab V2 (ranibizumab) |
| Enrollment | 180 |
| Start date | Aug 1, 2004 |
| Completion | Mar 1, 2007 |
| First posted | Sep 1, 2004 |
| Last update posted | Jun 21, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: